Figure 7.

LS-1-10 exhibits anticancer and autophagy-inhibiting activities in vivo. (a) Four-week-old nude mice were engrafted with DLD1 cells and randomly divided into four groups (n=6). After 2 weeks, the tumor-bearing mice were treated with PBS, LS-1-10 40 mg/kg, LS-1-10 80 mg/kg, or CQ 80 mg/kg by intraperitoneal injection every 5 per7 (5/7) days for 3 weeks. Tumor volumes were calculated by measuring the length and width using Vernier calipers every 2 days. Data represent the means±S.D. (n=6). (b) Images of the tumors from a. (c) Quantification of the tumor weights from (a). Student’s t-test, *P<0.05; **P<0.01. (d) Immunohistochemical staining of LC3 in tumor sections treated with PBS or LS-1-10. Four-week-old nude mice were engrafted with DLD1 cells and observed until tumors reached ~100mm³. Tumor-bearing mice were then treated with PBS or 20 μg LS-1-10 by intra-tumoral injection once every 2 days for a total of seven injections. Mice were killed and tumors were resected 2 days after the final injection